MUMBAI, India and WARREN, N.J., Nov. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and its wholly owned subsidiary Cipla USA Inc. (hereafter referred to as 'Cipla'), today ...

Read the Medication Guide provided by your pharmacist before you start using leuprolide and each time you get a refill. If you have any questions, ask your doctor or pharmacist. This medication is ...

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX), an integrated essential medicines company, announced Wednesday that it has received Abbreviated New Drug Application or ANDA approval from the U.S.

Combined mTOR and AKT inhibition in renal cell carcinoma (RCC). Background: Leuprolide acetate is a synthetic analog of gonadotropin hormone-releasing hormone (GnRH-a) that reduces serum testosterone ...

Please provide your email address to receive an email when new articles are posted on . A subcutaneous injection of leuprolide acetate every 6 months was effective and well tolerated in treating ...

(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, ...

Cipla is introducing leuprolide acetate injection depot, 22.5 mg, which is the generic of AbbVie’s Lupron Depot. It is indicated for palliative treatment of advanced prostate cancer. Leuprolide ...

The Food and Drug Administration has cleared Amneal’s leuprolide acetate for injection, which is indicated in the palliative treatment of advanced prostatic cancer. “We are making tremendous progress ...

CS21 was a three-arm, randomized (1:1:1), open-label, parallel-group Phase III trial of 12 months' duration incorporating adult male patients with histologically confirmed adenocarcinoma of the ...

The 6-month subcutaneously injectable leuprolide acetate (Fensolvi, Tolmar Pharmaceuticals) effectively and safely treats children with central precocious (early) puberty, research suggests. Findings ...

ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the ...